<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03779867</url>
  </required_header>
  <id_info>
    <org_study_id>RG1003977</org_study_id>
    <secondary_id>NCI-2018-02831</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>8766</secondary_id>
    <nct_id>NCT03779867</nct_id>
  </id_info>
  <brief_title>Acute Exercise Intervention in Reducing Breast Cancer Risk in Healthy Participants</brief_title>
  <acronym>ACE</acronym>
  <official_title>Acute Effects of Exercise in Women (ACE) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Breast Cancer Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well a bout of acute exercise in healthy participants can help reduce
      risk of breast cancer in healthy participants. An acute exercise intervention may affect
      factors associated with breast cancer and help doctors learn more about how exercise can help
      prevent breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants are randomized to 1 of 2 arms.

      ARM I: Participants undergo a moderate‐intensity acute exercise bout over 45 minutes.

      ARM II: Participants rest by sitting for 45 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>All study personnel other than the statisticians and exercise physiologist will be masked to participant study arm</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in homeostatic model assessment of insulin resistance (HOMA‐IR)</measure>
    <time_frame>Baseline up to 45 minutes</time_frame>
    <description>Will compare the average changes in HOMA‐IR from baseline to 45 minutes between the exercisers and controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in HOMA‐IR</measure>
    <time_frame>Baseline up to 105 minutes</time_frame>
    <description>Will compare the average changes in HOMA‐IR from baseline to 105 minutes between the exercisers and controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in insulin level</measure>
    <time_frame>Baseline up to 45 minutes</time_frame>
    <description>Will compare changes in insulin level from baseline to 45 minutes between the exercisers and controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in insulin level</measure>
    <time_frame>Baseline up to 105 minutes</time_frame>
    <description>Will compare changes in insulin level from baseline to 105 minutes between the exercisers and controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in glucose level</measure>
    <time_frame>Baseline up to 45 minutes</time_frame>
    <description>Will compare changes in glucose level from baseline to 45 minutes between the exercisers and controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in glucose level</measure>
    <time_frame>Baseline up to 105 minutes</time_frame>
    <description>Will compare changes in glucose level from baseline to 105 minutes between the exercisers and controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of exercise on HOMA‐IR in normal‐weight participants</measure>
    <time_frame>At 45 minutes</time_frame>
    <description>Will use the generalized estimating equations (GEE) model including the potential effect modification of weight category (normal weight versus [vs] overweight/obese) to compare the 45‐minute exercise session on HOMA‐IR in normal‐weight versus overweight/obese women.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of exercise on HOMA‐IR in overweight/obese participants</measure>
    <time_frame>At 45 minutes</time_frame>
    <description>Will use the GEE model including the potential effect modification of weight category (normal weight versus [vs.] overweight/obese) to compare the 45‐minute exercise session on HOMA‐IR in normal‐weight versus overweight/obese women.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Healthy Subject</condition>
  <condition>Breast Cancer Female</condition>
  <arm_group>
    <arm_group_label>Arm I (acute exercise)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo a moderate‐intensity acute exercise bout over 45 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (rest)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants rest by sitting for 45 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise Intervention</intervention_name>
    <description>Undergo acute exercise</description>
    <arm_group_label>Arm I (acute exercise)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Resting</intervention_name>
    <description>Seated resting</description>
    <arm_group_label>Arm II (rest)</arm_group_label>
    <other_name>Rest</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (acute exercise)</arm_group_label>
    <arm_group_label>Arm II (rest)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (acute exercise)</arm_group_label>
    <arm_group_label>Arm II (rest)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resident in greater Seattle metropolitan area (King County), Pierce or Snohomish
             Counties

          -  Healthy

          -  Able to perform all study requirements, including attendance at clinic visits and
             capable of responding to questionnaires and clinic and exercise facility instructions
             in English

          -  Willing to be randomized

          -  Capable of providing informed consent

        Exclusion Criteria:

          -  Pregnant in past 3 months

          -  Lactating

          -  Premenopausal women: irregular menstrual periods for the previous 6 months; no use of
             oral contraceptives for the previous 3 months, no use of hormone implants or
             intrauterine device (IUD) for in the previous year, no use of other sex hormones
             including testosterone or other androgens for the previous 3 months

          -  Postmenopausal women: no use of any sex hormones (estrogen, progesterone, testosterone
             or other androgens, for the previous 3 months) of any type including oral, creams,
             vaginal creams or inserts, patches, implants

          -  Current use of any tobacco products including smoking, vaping, chew, nicotine patches

          -  History of diabetes mellitus, or fasting glucose fingerstick &gt;= 126 mg/dL

          -  Taking any medications to treat high blood sugar such as metformin

          -  Personal history of invasive or in situ breast cancer

          -  Personal history of cancer other than breast: exceptions are non‐melanoma skin cancer
             and cervical neoplasia (CIN)

          -  &gt;= 2 alcoholic drinks/day

          -  Contraindications to exercise

          -  Abnormalities on screening physical that contraindicate participation

          -  Contraindications for entry into a research exercise program: recent (within 6 months)
             myocardial infarction, pulmonary edema, myocarditis, pericarditis, unstable angina,
             pulmonary embolism, deep vein thrombosis, uncontrolled hypertension (systolic &gt; 200,
             diastolic &gt; 100), orthostatic hypotension, moderate/severe aortic stenosis,
             uncontrolled arrhythmia, uncontrolled congestive heart failure, left bundle branch
             block, history of cardiac arrest or stroke

          -  Frequent marijuana use (&gt; 1 per month)

          -  Alcohol or drug abuse, significant mental illness (as assessed by study staff
             impression)

          -  History of clotting disorders (muscle‐biopsy sub study)

          -  Unable or unwilling to stop aspirin or nonsteroidal antiinflammatory drugs (NSAIDs)
             for 48 hours before and after the procedure (muscle‐biopsy sub study)

          -  Allergy to anesthetics or local anesthetics (muscle‐biopsy sub study)

          -  Long term use of warfarin or similar medications (muscle‐biopsy sub study)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne McTiernan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne McTiernan</last_name>
    <phone>206-667-7979</phone>
    <email>cduggan@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne McTiernan</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 17, 2018</study_first_submitted>
  <study_first_submitted_qc>December 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

